



Corrigendum

A fragment of secreted Hsp90 α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice

Chieh-Fang Cheng, Divya Sahu, Fred Tsen, Zhengwei Zhao, Jianhua Fan, Rosie Kim, Xinyi Wang, Kathryn O'Brien, Yong Li, Yuting Kuang, Mei Chen, David T. Woodley, and Wei Li

Original citation: *J Clin Invest.* 2011;121(11):4348–4361. doi:10.1172/JCI46475.

Citation for this corrigendum: *J Clin Invest.* 2012;122(2):779. doi:10.1172/JCI62538.

In Figure 2, concentrations of the recombinant Hsp90 α added to the real wounds in mice were inaccurate. The correct figure and legend appear below.



Figure 2

F-5 is superior to FDA-approved becaplermin/PDGF-BB in acute wound healing. Full-thickness skin wounds (1 cm \times 1 cm) in athymic nude mice were treated (only once on day 0) with either 200 μ l of 5% CMC gel (placebo) or the same volume of the gel containing an optimized concentration of a given peptide: (A) full-length, (B) F-2, (C) F-5, (D) F-6 ($n = 3$ mice per peptide, per experiment), or (E) becaplermin (20 μ g of PDGF-BB or 8 μ M). Plus signs indicate treated mice, and minus signs indicate placebo mice. The images of 1 representative experiment are shown.

The authors regret the error.